MiRNA-221 and miRNA-222 targeted KIT and restrained the KIT/AKT signaling pathway to inhibit cell proliferation, modify the progression of the cell cycle, induce apoptosis and reduce resistance in imatinib-resistant GIST cells (Gits et al., 2013; Ihle et al., 2015). The gene discussed is AKT1; the disease is gastrointestinal stromal tumor.